Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia

Recruiting N/A Interventional Study
Schizophrenia Healthy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
17 – 45
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
20 (estimated)
Sponsor
Centre for Addiction and Mental Health · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes. Additionally, almost half of the patients with SCZ are obese, the prevalence of type 2 diabetes is 3-6 times higher, and life expectancy is lower by 15-20 years compared to the general population. This is relevant as metabolic syndrome a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: i) Experimental group (participants with a diagnosis of schizophrenia spectrum disorder): 1. 17-45 years 2. both sexes; 3. Patients with first-episode schizophrenia spectrum illness: Primary DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, …
Contacts

Mahavir Agarwal, MD, PhD

416-535-8501

mahavir.agarwal@camh.ca

CONTACT

Laurie Hamel, MA

416-535-8501

laurie.hamel@camh.ca

CONTACT